[1]
Tsubuki, S.; Saito, Y.; Tomioka, M.; Ito, H.; Kawashima, S. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J. Biochem., 1996, 119(3), 572.
[2]
Galbiati, F.; Volonte, D.; Minetti, C.; Bregman, D.B.; Lisanti, M.P. Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutanta and rescues wild-type caveolin-3. J. Biochem., 2000, 275(48), 37702-37711.
[3]
Silke, M.; Antje, L.; Verena, S.; Karl, S. Proteasome inhibitors: Poisons and remedies. Med. Res. Rev., 2010, 28(2), 309-327.
[4]
Rock, K.L.; York, I.A.; Saric, T.; Goldberg, A.L. Protein degradation and the generation of MHC class I-presented peptides. Annu. Rev. Immunol., 1999, 17(17), 739-779.
[5]
Adams, J.; Palombella, V.J.; Sausville, E.A.; Johnson, J.; Destree, A.; Lazarus, D.D.; Maas, J.; Pien, C.S.; Prakash, S.; Elliott, P.J. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res., 1999, 59(11), 2615-2622.
[6]
Molineaux, S.M. Molecular pathways: Targeting proteasomal protein degradation in cancer. Clin. Cancer Res., 2012, 18(1), 15-20.
[7]
Potts, B.C.; Albitar, M.X.; Anderson, K.C.; Baritaki, S.; Berkers, C.; Bonavida, B.; Chandra, J.; Chauhan, D.; Cusack, J.C., Jr; Fenical, W.; Ghobrial, I.M.; Groll, M.; Jensen, P.R.; Lam, K.S.; Lloyd, G.K.; McBride, W.; McConkey, D.J.; Miller, C.P.; Neuteboom, S.T.; Oki, Y.; Ovaa, H.; Pajonk, F.; Richardson, P.G.; Roccaro, A.M.; Sloss, C.M.; Spear, M.A.; Valashi, E.; Younes, A.; Palladino, M.A. Marizomib, a proteasome inhibitor for all seasons: Preclinical profile and a framework for clinical trials. Curr. Cancer Drug Targets, 2011, 11(3), 254-284.
[8]
Ashok, A.; Damayanthi, D.; Sindhuja, T.; Esteves, S.C.; Avi, H.; Ralf, H.; Shubhadeep, R.; Sheryl, H.; Nicolás, G.P.; Ranjith, R.; Ahmad, M.; Kim, D.L.; Eva, T.; Mourad, A.; Kavindra, K.; Reecha, S.; Saleem, B.; Edmund, K.; Muhammad, A-E.; Jaime, G.; Asher, B. Bibliometrics: Tracking research impact by selecting the appropriate metrics. Asian J. Androl., 2016, 18(2), 296-309.
[9]
Bar-Ilan, J. Informetrics at the beginning of the 21st century-A review. J. Informetrics, 2008, 2(1), 1-52.
[10]
Ekinci, S.; Agilli, M.; Ersen, O.; Ekinci, G.H. Letter to the editor regarding analysis of changing paradigms of management in 179 patients with spinal tuberculosis during a 12-year period and proposal of a new management algorithm. World Neurosurg., 2015, 84(6), 2072.
[11]
Avcu, G.; Sahbudak, B.Z.; Duyu, M.; Akkus, E.; Karapinar, B.; Vardar, F. Thanks to trauma: A delayed diagnosis of pott disease. Pediatr. Emerg. Care, 2015, 31(12), e17-e18. [doi: 10.1097/PEC.0000000000000637].
[12]
King, D.A. The scientific impact of nations. Nature, 2004, 430(6997), 311-316.
[13]
Fu, H.Z.; Wang, M.H.; Ho, Y.S. Mapping of drinking water research: A bibliometric analysis of research output during 1992-2011. Sci. Total Environ., 2013, 443(3), 757-765.
[14]
Bornmann, L.; Daniel, H. The state of h index research: Is the h index the ideal way to measure research performance? EMBO Rep., 2009, 10(1), 2.
[15]
Synnestvedt, M.B.; Chen, C.; Holmes, J.H. CiteSpace II: Visualization and knowledge discovery in bibliographic databases. AMIA Annu. Symp. Proc., 2005, 2005, 724-728.
[16]
Kisselev, A.F.; Goldberg, A.L. Proteasome inhibitors: From research tools to drug candidates. Chem. Biol., 2001, 8(8), 739-758.
[17]
Adams, J.; Behnke, M.; Chen, S.; Cruickshank, A.A.; Dick, L.R.; Grenier, L.; Klunder, J.M.; Ma, Y.T.; Plamondon, L.; Stein, R.L. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids. Bioorg. Med. Chem. Lett., 1998, 8(4), 333.
[18]
Orlowski, R.Z.; Voorhees, P.M.; Garcia, R.A.; Hall, M.D.; Kudrik, F.J.; Allred, T. Johri. A.R.; Jones, P.E.; Ivanova, A.; Van Deventer, H.W.; Gabriel, D.A.; Shea, T.C.; Mitchell, B.S.; Adams, J.; Esseltine, D.L.; Trehu, E.G.; Green, M.; Lehman, M.J.; Natoli, S.; Collins, J.M.; Lindley, C.M.; Dees, E.C. Phase I trial of the proteasome inhibitor bortezomib and pegylate liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 2005, 105(8), 3058.
[19]
Zhang, J.; Yu, Q.; Zheng, F.; Long, C.; Lu, Z.; Duan, Z. Comparing keywords plus of WOS and author keywords: A case study of patient adherence research. J. Assoc. Inf. Sci. Technol., 2016, 67(4), 967-972.
[20]
Li, L.L.; Ding, G.; Feng, N.; Wang, M.H.; Ho, Y.S. Global stem cell research trend: Bibliometric analysis as a tool for mapping of trends from 1991 to 2006. Scientometrics, 2009, 80(1), 39-58.
[21]
Dick, T.P.; Nussbaum, A.K.; Deeg, M.; Heinemeyer, W.; Groll, M.; Schirle, M.; Keilholz, W.; Stevanović, S.; Wolf, D.H.; Huber, R.; Rammensee, H.G.; Schild, H. Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J. Biol. Chem., 1998, 273(40), 25637-25646.
[22]
Kumeda, S.I.; Deguchi, A.; Toi, M.; Omura, S.; Umezawa, K. Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells. Anticancer Res., 1999, 19(5B), 3961-3968.
[23]
Machiels, B.M.; Henfling, M.E.; Gerards, W.L.; Broers, J.L.; Bloemendal, H.; Ramaekers, F.C.; Schutte, B. Detailed analysis of cell cycle kinetics upon proteasome inhibition. Cytometry, 1997, 28(3), 243-252.
[24]
Wang, X.; Luo, H.; Chen, H.; Duguid, W.; Wu, J. Role of proteasomes in T cell activation and proliferation. J. Immunol., 1998, 160(2), 788-801.
[25]
Lopes, U.G.; Erhardt, P.; Yao, R.; Cooper, G.M. p53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem., 1997, 272(20), 12893-12896.
[26]
Li, B.; Dou, Q.P. Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression. Proc. Natl. Acad. Sci. USA, 2000, 97(8), 3850-3855.
[27]
Meriin, A.B.; Gabai, V.L.; Yaglom, J.; Shifrin, V.I.; Sherman, M.Y. Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis. Biol. Chem., 1998, 273(11), 6373-6379.
[28]
Van-Antwerp, D.J.; Martin, S.J.; Verma, I.M.; Green, D.R. Inhibition of TNF-induced apoptosis by NF-kappa B. Trends Cell Biol., 1998, 8(3), 107-111.
[29]
Drexler, H.C.; Risau, W.; Konerding, M.A. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J., 2000, 14(1), 65-77.
[30]
Orlowski, R.; Eswara, J.; Lafond-Walker, A.; Grever, M.; Orlowski, M.; Dang, C. Tumor growth inhibition induced in a murine model of human Burkitt’s lymphoma by a proteasome inhibitor. Cancer Res., 1998, 58(19), 4342-4348.
[31]
An, B.; Goldfarb, R.H.; Siman, R.; Dou, Q.P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ., 1998, 5(12), 1062-1075.
[32]
Masdehors, P.; Omura, S.; Merle-Béral, H.; Mentz, F.; Cosset, J.M. Dumont. J.; Magdelénat, H.; Delic, J. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br. J. Haematol., 1999, 105(3), 752-757.
[33]
Drexler, H.C. Activation of the cell death program by inhibition of proteasome function. Proc. Natl. Acad. Sci. USA, 1997, 94(3), 855-860.
[34]
Yao, Q.; Chen, K.; Yao, L.; Lyu, P.H.; Yang, T.A.; Luo, F.; Chen, S.Q.; He, L.Y.; Liu, Z.Y. Scientometric trends and knowledge maps of global health systems research. Health Res. Policy Syst., 2014, 12(1), 1-20.
[35]
O’Connor, O.A.; Stewart, A.K.; Vallone, M.; Molineaux, C.J.; Kunkel, L.A.; Gerecitano, J.F.; Orlowski, R.Z. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin. Cancer Res., 2009, 15(22), 7085-7091.
81
2
1
1